RxDoctor Payments Data

Iga Ntheketha, NP

Nurse Practitioner · Rochester, NYNPI 1114511664

Payments from drug & device makers

$728in general payments, 2019–2025

Across 16 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$278
  • Optinose US, Inc.$244
  • GSK$206

What the payments were for

  • Food & beverage$728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.11$278
Optinose US, Inc.3$244
GSK2$206

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$728 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$423,119
Medicare patients
251
Services billed
5,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate18$69,026
EliquisApixaban98$31,672
RexultiBrexpiprazole40$28,138
XareltoRivaroxaban54$16,337
PrezcobixDarunavir/Cobicistat12$16,153
TrulicityDulaglutide12$11,874
VraylarCariprazine Hcl16$11,238
SantylCollagenase Clostridium Hist.16$8,047
Combivent RespimatIpratropium/Albuterol Sulfate14$7,389
Incruse ElliptaUmeclidinium Bromide24$6,990
FarxigaDapagliflozin Propanediol23$6,647
JardianceEmpagliflozin13$5,385
KonvomepOmeprazole/Sodium Bicarbonate15$4,799
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$4,045
Atorvastatin Calcium304$3,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKIncruse Ellipta$206$6,99024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →